个人简介：

Dr. Kevin Pan is a co-founder of Asieris Pharmaceuticals and has served as chairman of the board and CEO since Mach 2010. Asieris is a private, VC-backed clinical-stage biotech company based in China and with clinical operations in the US. Before founding Asieris, Dr. Pan was a founding member of Hutchison MediPharma, a leading Chinese biopharmaceutical company listed on AIM and Nasdaq. He served as the senior director of drug discovery chemistry and IP at the beginning, and then led the company’s business development with a successful track record of partnership deals with P&G and Merck Serono. Dr. Pan started his career in the pharmaceutical industry from the R&D divisions at Pfizer (Groton, CT) and Johnson & Johnson (Spring House, PA).  Dr. Pan received a BS degree in organic chemistry from Fudan University in Shanghai and a Ph.D. degree in bioorganic chemistry from Rutgers, the State University of New Jersey. He had been a joint professor at the School of Pharmacy of Jilin University in China from 2005-2010, and is currently members of the Bayhelix Group and Chinese Society of Clinical Oncology (CSCO).

公司简介：

亚虹医药在2010年3月成立于江苏省泰州市中国医药城（中国首家国家级的医药高新技术产业园区），目前在上海张江高科技园区设有临床研究、抗肿瘤机制研究、以及商务拓展团队，在美国设有国际临床开发和商务拓展机构。 

我们的愿景是致力于成为一个立足中国、面向全球，在抗肿瘤和抗耐药感染领域中具有一定国际影响力的新药研发企业。我们充分利用老药的丰富临床经验在重大疾病领域进行突破性创新。

我们的创始人团队和管理团队既包括多位在美国大型制药企业工作20 余年的行业专家，也吸引了一批在国内跨国企业和本土企业成长起来的管理人员。他们具有丰富的国内新药研发经验，并怀有追赶国外浪潮的远大理想。

我们的领军药物APL-1202可望成为全球第一个口服治疗非肌层浸润性膀胱癌的药物，曾获得国家“十二五重大新药创制”专项等多项政府资助。APL-1202治疗灌注复发的非肌层浸润性膀胱癌II期临床研究表现了显著的疗效，研究结果在2016年欧洲泌尿外科协会慕尼黑年会上报告。APL-1202正在中国进行注册性临床试验，其第二代产品APL-1301即将开展国际临床开发。亚虹医药还有多项全新作用机制的抗肿瘤、抗多药耐药感染的新药项目处于临床前开发阶段。

公司官网：http://www.asieris.cn/